On Air Now

Current Show

The Mark Levin Show   5:00 PM - 8:00 PM

Call The Mark Levin Show at 1-877-381-3811

Show Info »

Upcoming Shows

Program Schedule »


Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI


Current Conditions(Wausau,WI 54403)

More Weather »
66° Feels Like: 66°
Wind: SW 10 mph Past 24 hrs - Precip: 0”
Current Radar for Zip


Clear 44°


Sunny 72°

Tues Night

Partly Cloudy 47°


Breaking News

BREAKING NEWS / UPDATE: Wausau police confirm Stephanie Low's body was found in Wabeno; person of interest Kristopher Torgerson to be charged with homicide

WAUSAU, Wis (WSAU)  Wausau police say Stephanie Low's body has been found. Police revealed at a news conference today that a person of interest in her death, Kristopher Torgerson, led police to her body on September 19th. The body has since been positively ID'ed by the state crime lab. The autopsy lists 'homicide' as the cause of death. Torgerson had been questioned nearly four years ago after she had first disappeared. Wausau PD say he was in custody on other charges, and agreed to sh...

Read More »

Vivus's obesity pill to be covered by Express Scripts

(Reuters) - Vivus Inc said its obesity drug Qsymia will now be covered by the largest U.S. pharmacy benefits manager Express Scripts Holding Co, giving more people access to the drug and reducing costs for patients.

Express Scripts added Qsymia as a standard benefit option to its national formulary, which means patients will now pay about $50 to $60 as their co-payment on a monthly prescription of Qsymia, or about one-third of the retail price.

The drug is currently available only through mail-order pharmacies for an average retail price of $160.

Vivus's Chief Commercial Officer Mike Miller said last month that about 30 percent of patients receiving a Qsymia prescription did not buy the drug because of the cost.

Vivus's shares rose 8 percent to a high of $14.71 in early trade on the Nasdaq.

"We believe that it is a positive sign for longer-term success on the reimbursement that Vivus has been able to make these inroads during the first three months of the launch," Cowen & Co analyst Simos Simeonidis wrote in a note.

The analyst, however, maintained his "neutral" rating on the stock, saying it was unclear how many people would benefit from Express Scripts' policy change.

Initial sales of Qsymia, one of the two new diet pills approved earlier this year after a dry spell of 13 years, were weak largely due to the lack of reimbursement coverage for the drug.

Lackluster sales also prompted investor activism against Vivus, with its top shareholders calling for a sale of the company.

However, the third-largest U.S. health insurer Aetna Inc last month said it would provide coverage for both diet pills - Qsymia and Arena Pharmaceuticals Inc's Belviq.

(Reporting by Esha Dey and Zeba Siddiqui in Bangalore; Editing by Roshni Menon)